0000899243-18-003459.txt : 20180209
0000899243-18-003459.hdr.sgml : 20180209
20180209200605
ACCESSION NUMBER: 0000899243-18-003459
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180207
FILED AS OF DATE: 20180209
DATE AS OF CHANGE: 20180209
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Montgomery Alan Bruce
CENTRAL INDEX KEY: 0001313936
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-49908
FILM NUMBER: 18593567
MAIL ADDRESS:
STREET 1: 1111 MAIN STREET, SUITE 660
CITY: VANCOUVER
STATE: WA
ZIP: 98660
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CytoDyn Inc.
CENTRAL INDEX KEY: 0001175680
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 753056237
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0531
BUSINESS ADDRESS:
STREET 1: 1111 MAIN STREET, SUITE 660
CITY: VANCOUVER
STATE: WA
ZIP: 98660
BUSINESS PHONE: 360-980-8524
MAIL ADDRESS:
STREET 1: 1111 MAIN STREET, SUITE 660
CITY: VANCOUVER
STATE: WA
ZIP: 98660
FORMER COMPANY:
FORMER CONFORMED NAME: CYTODYN INC
DATE OF NAME CHANGE: 20031114
FORMER COMPANY:
FORMER CONFORMED NAME: REXRAY CORP
DATE OF NAME CHANGE: 20020617
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-02-07
0
0001175680
CytoDyn Inc.
CYDY
0001313936
Montgomery Alan Bruce
1111 MAIN STREET, SUITE 660
VANCOUVER
WA
98660
1
0
0
0
Stock Options (right to buy)
0.56
2018-02-07
4
A
0
136563
A
2018-02-07
2028-02-07
Common Stock
136563
136563
D
On February 7, 2018, the board of directors of CytoDyn Inc. approved an amendment to its director compensation program, providing for payment in stock options, in lieu of cash, of all unpaid director retainer fees for the four-quarter period ending February 28, 2018. The number of options awarded to each director was determined by applying a price of $0.31 per option, which was the fair value estimate of the option award as of the grant date, using the Black-Scholes option pricing model
/s/ Michael D. Mulholland, as attorney-in-fact
2018-02-09